- Home
- WHF vs RVNC Comparison
WHF vs RVNC Comparison
Compare WHF & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- RVNC
- Stock Information
- Founded
- WHF 2011
- RVNC 1999
- Country
- WHF United States
- RVNC United States
- Employees
- WHF N/A
- RVNC N/A
- Industry
- WHF Finance Companies
- RVNC Biotechnology: Pharmaceutical Preparations
- Sector
- WHF Finance
- RVNC Health Care
- Exchange
- WHF Nasdaq
- RVNC Nasdaq
- Market Cap
- WHF 275.2M
- RVNC 546.4M
- IPO Year
- WHF 2012
- RVNC 2014
- Fundamental
- Price
- WHF $11.91
- RVNC $5.29
- Analyst Decision
- WHF Hold
- RVNC Buy
- Analyst Count
- WHF 3
- RVNC 10
- Target Price
- WHF $12.75
- RVNC $10.86
- AVG Volume (30 Days)
- WHF 55.7K
- RVNC 1.3M
- Earning Date
- WHF 11-07-2024
- RVNC 11-06-2024
- Dividend Yield
- WHF 12.96%
- RVNC N/A
- EPS Growth
- WHF 62.93
- RVNC N/A
- EPS
- WHF 0.98
- RVNC N/A
- Revenue
- WHF $100,458,000.00
- RVNC $251,178,000.00
- Revenue This Year
- WHF N/A
- RVNC $20.36
- Revenue Next Year
- WHF N/A
- RVNC $31.66
- P/E Ratio
- WHF $12.09
- RVNC N/A
- Revenue Growth
- WHF 1.22
- RVNC 40.23
- 52 Week Low
- WHF $10.95
- RVNC $2.30
- 52 Week High
- WHF $13.44
- RVNC $9.75
- Technical
- Relative Strength Index (RSI)
- WHF 55.90
- RVNC 44.50
- Support Level
- WHF $11.77
- RVNC $5.10
- Resistance Level
- WHF $11.98
- RVNC $5.43
- Average True Range (ATR)
- WHF 0.17
- RVNC 0.17
- MACD
- WHF 0.04
- RVNC 0.02
- Stochastic Oscillator
- WHF 80.70
- RVNC 66.67
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate attractive risk-adjusted returns for investors, primarily by originating senior secured loans to privately held small-cap companies across a broad range of industries.
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.